So, what To Expect From GSK1120212?

AFFIRM subgroup analyses Additional analyses of the AFFIRM trial have demonstrated that the PS341 benefits of enzalutamide are observed across different subgroups. Given that prostate cancer is predominantly a disease of older men and older patients are more likely to present with advanced disease, with many patients not receiving optimal treatment due to decisions based on age alone, it was of interest to determine if there were any differential age-related effects of enzalutamide treatment. In a post hoc analysis, enzalutamide treatment resulted in a similar survival benefit in patients ?75 years and 0.78; median not yet reached versus 13.6 months; and patients ?75 years: HR 0.61; 95% CI 0.43, 0.86; median 18.2 months versus 13.3 months). The superiority of enzalutamide over placebo was also shown for all secondary endpoints for both age groups, including radiographic progression-free survival (rPFS), time to prostate-specific antigen (PSA) progression and PSA response rate. The majority of patients in the AFFIRM trial were recruited from Europe (EU) and North America (NA). These regions have different clinical management, diagnosis and treatment guidelines for prostate cancer across the disease spectrum, which may influence disease recurrence this website and progression patterns. Therefore, it was of interest to explore if there were any differences in outcomes between EU and NA patients through a post hoc analysis of the AFFIRM study. Enzalutamide significantly improved OS compared with placebo in both EU and NA patients [Merseburger et al. 2014]. Of note, the median OS in EU patients was longer than in NA patients in both treatment groups. However, lazabemide the relative treatment effect, expressed as HR (and 95% CI), was similar in both regions: 0.64 (0.50, 0.82) for EU and 0.63 (0.47, 0.83) for NA. The benefit of enzalutamide over placebo was consistent across all secondary endpoints in patients in both regions, with significant improvements (p?